Novo Nordisk To Reveal The Huge Demand For Its Weight Loss Drugs

Pharma Giant Novo Nordisk will reveal the massive demand for weight loss drugs, such as Ozempic and Wegovy. The Danish company has experienced a significant boost in revenues, driven by the soaring demand for its diabetes and weight-loss medications, Ozempic and Wegovy. According to an analysis report, sales of  £7.7billion are estimated between April and June. Last year it was about £3.9billion for the same quarter.

Wegovy, the drug used to treat obesity, is an injection that tricks the body into making it feel full. The medicine is available on the NHS and is prominently famous in the U.S. Celebrities like Rebel Wilson. Over the past year, a 64% rise has been noticed in shares. The current worth of Novo Nordisk is worth £210billion.